Retrospective Observational Study on Prediction of Response to PD-1 Immunotherapy in Patients with NSCLC

Launched by UNIVERSITY HOSPITAL, BREST · May 10, 2021

Keywords

ClinConnect Summary

The PREDICTION study is looking at how to better understand which patients with advanced non-small cell lung cancer (NSCLC) will respond well to a treatment called pembrolizumab, a type of immunotherapy. Immunotherapy works by helping the body’s immune system fight cancer, but not everyone benefits from it. This study aims to find out why some patients respond well to this treatment while others do not, and it will also examine any side effects that may occur. By analyzing tumor samples from patients who received pembrolizumab, researchers hope to identify specific markers that can predict both the effectiveness of the treatment and any potential side effects.

To be eligible for this study, participants must be adults with advanced NSCLC that has a high level of a protein called PD-L1 (50% or greater). They should have started treatment with pembrolizumab for the first time between January 2017 and December 2019. Individuals with autoimmune diseases, those who have previously received immunotherapy, or those who started pembrolizumab after December 2019 are not eligible to participate. If you join this study, you can expect to contribute to important research that may help improve treatment strategies for future patients with similar conditions.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adult patients
• • Advanced NSCLC with PD-L1 TPS of 50% or greater
• • Administration of first line pembrolizumab between January 2017 \& December 2019
• Exclusion Criteria:
• • Auto-immune disease
• • Prior exposure to immunotherapy
• • First dose pembrolizumab administered after December 2019